Tectonic Therapeutic, Inc.
TECX · XNASCIK 1681087fmd_08GGRDDPMZ702A5SNM4SPQ416JManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 38 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Research and development | 15 | 35 | 55 | 87 | 83 | 72 | 37 | 41 | 63 |
| Total operating expenses | 18 | 46 | 76 | 120 | 119 | 105 | 45 | 58 | 84 |
| Operating income | (18) | (46) | (76) | (120) | (119) | (105) | (45) | (58) | (84) |
| Interest expense | – | – | – | – | 0 | 2 | 0 | 0 | 0 |
| Interest and investment income | 0 | 2 | 3 | 1 | – | – | 1 | 4 | 11 |
| Other non-operating income (expense) | (0) | (0) | 3 | 1 | (0) | (0) | 2 | 0 | 11 |
| Income before taxes | – | – | – | – | – | – | – | (58) | (73) |
| Income tax expense | – | – | – | – | – | 0 | 0 | 0 | 1 |
| Net income from continuing operations | – | – | – | – | – | – | – | (58) | (74) |
| Net income | (19) | (46) | (73) | (120) | (119) | (106) | (43) | (58) | (74) |
| Net income to common shareholders | – | – | – | – | – | (106) | (43) | (58) | (74) |